BioMarin acquires Alesta Therapeutics

"Jones Day advised BioMarin Pharmaceutical Inc. on the acquisition of Alesta Therapeutics B.V. for $275 million in upfront cash and up to $215 million in contingent milestone payments. Alesta will spin out all non-ALE 1 assets into a newly formed entity immediately prior to closing."

Jones Day advised BioMarin Pharmaceutical Inc. in its acquisition of Alesta Therapeutics B.V. The transaction provides for $275 million in upfront cash consideration, plus up to $215 million in contingent milestone payments. Immediately prior to closing, Alesta will spin out all of its non-ALE 1 assets to a newly formed entity. Jones Day represented client(s) BioMarin Pharmaceutical Inc. with a team composed by: Jonn R. Beeson, Benjamin Chouka.

Read the full story

Already registered? Login

Menu

BioMarin acquires Alesta Therapeutics

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads